As of November 6, 2026, Alnylam Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: ALNY); its largest reported holder is Fidelity (FMR), with 9.5% on Schedule 13G/A of November 5, 2026, then Capital World Investors (8.2%). The largest insider holding is Phillip A. Sharp, a director, with 266,899 shares (0.20% of shares outstanding) held indirectly through a trust, per Form 4 of January 24, 2025 (Schedule 13G/A, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Alnylam Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Alnylam Pharmaceuticals, Inc. a real, registered company?
- Alnylam Pharmaceuticals Inc files with the SEC under CIK 1178670 (its SEC filings).
- Its shares are listed under the ticker ALNY on Nasdaq (SEC company record).
- business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ALNYLAM PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Tolga Tanguler, Chief Commercialization Officer (Form 8-K filed 2026-11-05). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Alnylam Pharmaceuticals, Inc.'s owners and officers?
Alnylam Pharmaceuticals, Inc.: business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Form D, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 9.5% |
| Schedule 13G, 2026-10-30 | Vanguard Portfolio Management | 5.03% |
| Schedule 13G/A, 2026-05-14 | Capital Research Global Investors | 7.1% |
| Schedule 13G/A, 2026-05-14 | Capital World Investors | 8.2% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 11% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.35% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 12.8% |
Questions about who owns Alnylam Pharmaceuticals, Inc.
Who owns Alnylam Pharmaceuticals, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Alnylam Pharmaceuticals, Inc.: Fmr LLC (9.5%, Schedule 13G/A, filed 2026-11-05), Capital World Investors (8.2%, Schedule 13G/A, filed 2026-05-14), Capital Research Global Investors (7.1%, Schedule 13G/A, filed 2026-05-14), Vanguard Capital Management (5.35%, Schedule 13G, filed 2026-04-29) and Vanguard Portfolio Management (5.03%, Schedule 13G, filed 2026-10-30).
Who are the largest shareholders of Alnylam Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Alnylam Pharmaceuticals, Inc. on this page are Fmr LLC (9.5%), Capital World Investors (8.2%) and Capital Research Global Investors (7.1%).
When did Fmr LLC buy into Alnylam Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-11-05, reporting 12.8%; its latest, Schedule 13G/A filed 2026-11-05, reports 9.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Alnylam Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Alnylam Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alnylam Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-05 | Tolga Tanguler | Chief Commercialization Officer | departed | |
| Form 8-K, 2026-05-27 | Benjamin F. Cravatt | appointed | 2026-06-01 |
Which insiders own Alnylam Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 266,899 shares (0.20% of shares outstanding), held indirectly through a trust (Form 4, 2025-01-24).
- , the chief executive and a director: 96,209 shares (0.07% of shares outstanding), 95,802 held directly and 407 indirectly (Form 4, 2026-09-22).
- , the chief financial officer and executive vice president: 61,862 shares (0.05% of shares outstanding), 61,805 held directly and 57 indirectly (Form 4, 2026-03-06).
- , the executive vice president and chief commercial officer: 34,297 shares (0.03% of shares outstanding) (Form 4, 2026-03-06).
- , a director: 29,482 shares (0.02% of shares outstanding), 1,582 held directly and 27,900 indirectly (Form 4, 2026-06-03).
Shares outstanding: 133,937,576 as of 2026-10-23, from the company's latest SEC cover page.
How much has Alnylam Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Alnylam Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Alnylam Pharmaceuticals, Inc. and the records around it.
Alnylam Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes May 2026
Companies that share a holder
- Capital Research Global Investors also filed stake reports on 99 other companies: Royal Caribbean Cruises Ltd. (Oct 2026), Patria Investments Ltd. (Sep 2026), Arxis, Inc. (Aug 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/alnylam-pharmaceuticals